

AnorMED Inc.  
Form 6-K  
September 11, 2006

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

---

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**For the month of September 2006**

**Commission File Number 1-32654**

---

**ANORMED INC.**

*(Translation of registrant's name into English)*

#200 20353 64 Avenue

Langley, British Columbia

Canada V2Y 1N5

*(Address of principal executive offices)*

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [  ] Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ] No [X]

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_.

---

### **INCORPORATION BY REFERENCE**

Exhibit 99.1 to this Form 6-K shall be incorporated by reference into the Prospectus and Registration Statement on Form S-8 of AnorMED Inc. (File No. 333-135097).

### **DOCUMENTS FILED**

See the Exhibit Index hereto for a list of the documents filed herewith and forming a part of this Form 6-K.

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**ANORMED INC.**

By:

/s/ W. J. Adams

Name: William J. (Bill) Adams

Title:

Title: Chief Financial Officer,  
Vice President, Finance, Secretary and Treasurer

Date: September 11, 2006

---

**EXHIBIT INDEX**

<u>Exhibit</u>	<u>Description</u>
99.1	Material Change Report (Form 51-102F3) dated September 11, 2006.

---

**FORM 51-102F3**

**MATERIAL CHANGE REPORT**

***Item 1. Name and Address of Company***

AnorMED Inc. (the Company )

Suite 200, 20353 - 64<sup>th</sup> Avenue

Langley, British Columbia V2Y 1N5

***Item 2. Date of Material Change***

September 1, 2006, in respect of an unsolicited take-over bid from Genzyme Corporation ( Genzyme ).

September 5, 2006, in respect of the filing of a Directors Circular and the Board of Directors adoption of a limited duration shareholder rights plan.

***Item 3. News Release***

On September 1, 2006, the Company issued a press release relating to an unsolicited take-over bid from Genzyme. The press release was disseminated via Canada NewsWire.

On September 5, 2006, the Company issued a press release relating to the filing of a Directors Circular and the adoption of a limited duration shareholder rights plan. The press release was disseminated via Canada NewsWire.

***Item 4. Summary of Material Change***

The Company announced on September 1, 2006 that Genzyme commenced an unsolicited take-over bid.

The Company announced on September 5, 2006 that it filed a Directors Circular with securities regulators in Canada and the United States, and adopted a limited duration shareholder rights plan.

***Item 5. Full Description of Material Change***

The Company announced on September 1, 2006 that Genzyme, through a wholly-owned subsidiary, commenced an unsolicited take-over bid to purchase all of the issued and outstanding common shares of the Company for U.S.\$8.55 per share in cash. The Company advised shareholders to defer making any determination with respect to the Genzyme Offer until a Directors Circular and the related Solicitation/Recommendation Statement on Schedule 14D-9 is prepared and filed by the Company.

The Company announced on September 5, 2006 that it filed its Directors Circular with securities regulators in Canada and the United States. The Directors Circular recommends to the Company's shareholders that they reject the Genzyme Offer and not tender their shares.

The Company also announced on September 5, 2006 that its Board of Directors approved the adoption of a limited duration shareholder rights plan (the Rights Plan ), effective as of August 29, 2006 subject to Toronto Stock Exchange approval. The Rights Plan will be filed and will be available on the United States Securities Commission ( SEC ) website at [www.sec.gov](http://www.sec.gov) and at [www.sedar.com](http://www.sedar.com).



***Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102***

Not applicable.

***Item 7. Omitted Information***

No significant facts remain confidential and no information has been omitted in this report.

***Item 8. Executive Officer***

**Name of Executive Officer:**

W.J. (Bill) Adams

Chief Financial Officer, Vice President, Finance,  
Secretary and Treasurer

**Telephone Number:**

604-530-1057

***Item 9. Date of Report***

September 11, 2006

**ANORMED INC.**

/s/ W.J. Adams

Signature

W.J. (Bill) Adams,

Chief Financial Officer, Vice President, Finance, Secretary  
and Treasurer

Name and Position of Signatory